The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial.
 
Katrin Marie Sjoquist
Honoraria - BMS; Merck; MSD; Novotech (Inst); Novotech (Inst); SERVIER
Research Funding - Bayer (Inst)
Other Relationship - Novotech
 
Alexander Dobrovic
No Relationships to Disclose
 
Kristy Robledo
No Relationships to Disclose
 
Sally E. Baron-Hay
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck Sharpe and Doehme; Novartis; Pfizer; Roche
Speakers' Bureau - MSD Oncology
Travel, Accommodations, Expenses - Gilead Sciences; MSD Oncology
 
Sumitra Ananda
No Relationships to Disclose
 
Nicole J. McCarthy
Consulting or Advisory Role - AstraZeneca
 
Jeffrey C. Goh
Stock and Other Ownership Interests - ICON Cancer Care; Immutep
Honoraria - Ipsen; MSD Oncology
Consulting or Advisory Role - BMS; GlaxoSmithKline; Janssen Oncology; MSD
Speakers' Bureau - AstraZeneca/MedImmune; Ipsen; Janssen; MSD Oncology; Pfizer/EMD Serono
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - Bayer; Pfizer/EMD Serono
 
Nicholas Murray
Employment - Adelaide Oncology & Haematology; GenesisCare
Leadership - Adelaide Oncology & Haematology; GenesisCare
Stock and Other Ownership Interests - Adelaide Oncology & Haematology; GenesisCare
Honoraria - Gilead Sciences
Consulting or Advisory Role - Gilead Sciences
Travel, Accommodations, Expenses - Novartis
 
Christopher B. Steer
Honoraria - AstraZeneca; Eisai; MSD Oncology; Mundipharma; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Ipsen; Janssen; MSD; Sanofi
Expert Testimony - Janssen
Travel, Accommodations, Expenses - Janssen
 
Sonia Yip
No Relationships to Disclose
 
Linda R. Mileshkin
Research Funding - BeiGene (Inst)
 
Olga Kondrashova
Consulting or Advisory Role - Xing Technologies
 
J. Lynn Fink
No Relationships to Disclose
 
Garry Chang
No Relationships to Disclose
 
Lisa Bailey
No Relationships to Disclose
 
Yvonne Lee
No Relationships to Disclose
 
Danka Sinikovic Zebic
Speakers' Bureau - Merck
 
Cassandra J. Vandenberg
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Eisai Europe (Inst); Sierra Oncology (Inst)
 
Clare L. Scott
Consulting or Advisory Role - Oncology One
Research Funding - AstraZeneca; Clovis Oncology; Eisai; Sierra Oncology
Patents, Royalties, Other Intellectual Property - Royalty agreement for venetoclax (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Eisai; Epsila Bio; GlaxoSmithKline; MSD Oncology; Sierra Oncology; Takeda
 
Paul Michael Waring
Employment - AstraZeneca
Leadership - ORI healthcare; Pillar Biosciences; Xing Technologies
Stock and Other Ownership Interests - Pillar Biosciences; Roche (I); Roche/Genentech; Xing Technologies
Consulting or Advisory Role - ORI Healthcare; Pillar Biosciences; Xing Technologies
Travel, Accommodations, Expenses - AstraZeneca; Pillar Biosciences; Xing Technologies